The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.
Adult
Aged
Aged, 80 and over
Anthropometry
/ methods
Biomarkers, Tumor
/ blood
Cross-Sectional Studies
Humans
Insulin-Like Growth Factor Binding Proteins
/ blood
Insulin-Like Growth Factor I
/ metabolism
Insulin-Like Growth Factor II
/ metabolism
Male
Middle Aged
Neoplasms
/ blood
Prospective Studies
Young Adult
IGFBPs
IGFs
correlates
pooled analysis
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 12 2019
15 12 2019
Historique:
received:
18
10
2018
revised:
28
01
2019
accepted:
04
02
2019
pubmed:
16
3
2019
medline:
31
1
2020
entrez:
16
3
2019
Statut:
ppublish
Résumé
Insulin-like growth factors (IGFs) and insulin-like growth factor binding proteins (IGFBPs) have been implicated in the aetiology of several cancers. To better understand whether anthropometric, behavioural and sociodemographic factors may play a role in cancer risk via IGF signalling, we examined the cross-sectional associations of these exposures with circulating concentrations of IGFs (IGF-I and IGF-II) and IGFBPs (IGFBP-1, IGFBP-2 and IGFBP-3). The Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset includes individual participant data from 16,024 male controls (i.e. without prostate cancer) aged 22-89 years from 22 prospective studies. Geometric means of protein concentrations were estimated using analysis of variance, adjusted for relevant covariates. Older age was associated with higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGF-I, IGF-II and IGFBP-3. Higher body mass index was associated with lower concentrations of IGFBP-1 and IGFBP-2. Taller height was associated with higher concentrations of IGF-I and IGFBP-3 and lower concentrations of IGFBP-1. Smokers had higher concentrations of IGFBP-1 and IGFBP-2 and lower concentrations of IGFBP-3 than nonsmokers. Higher alcohol consumption was associated with higher concentrations of IGF-II and lower concentrations of IGF-I and IGFBP-2. African Americans had lower concentrations of IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 and Hispanics had lower IGF-I, IGF-II and IGFBP-3 than non-Hispanic whites. These findings indicate that a range of anthropometric, behavioural and sociodemographic factors are associated with circulating concentrations of IGFs and IGFBPs in men, which will lead to a greater understanding of the mechanisms through which these factors influence cancer risk.
Identifiants
pubmed: 30873591
doi: 10.1002/ijc.32276
pmc: PMC6745281
mid: EMS84214
doi:
Substances chimiques
Biomarkers, Tumor
0
Insulin-Like Growth Factor Binding Proteins
0
Insulin-Like Growth Factor I
67763-96-6
Insulin-Like Growth Factor II
67763-97-7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3244-3256Subventions
Organisme : Medical Research Council
ID : MR/K02700X/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : UM1 CA164973
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : Cancer Research UK
ID : A20986
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C18281/A19169
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700474
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A19169
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9900923
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A20986
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Informations de copyright
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Diabetologia. 2001 Mar;44(3):333-9
pubmed: 11317665
J Clin Invest. 2017 Jan 3;127(1):1-4
pubmed: 28045402
J Clin Endocrinol Metab. 1989 Jan;68(1):135-40
pubmed: 2462571
Hepatology. 2017 Dec;66(6):2002-2015
pubmed: 28653763
Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1107-10
pubmed: 10613344
Lancet Oncol. 2011 Aug;12(8):785-94
pubmed: 21782509
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Lung Cancer. 2004 Aug;45 Suppl 2:S3-9
pubmed: 15552776
Cancer Res. 2016 Apr 15;76(8):2288-2300
pubmed: 26921328
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Br J Cancer. 2004 Oct 18;91(8):1525-31
pubmed: 15354219
Endocr Relat Cancer. 2010 Jan 29;17(1):51-60
pubmed: 19786462
Public Health Nutr. 2003 Apr;6(2):175-80
pubmed: 12675960
BMC Med. 2017 Jul 13;15(1):115
pubmed: 28701188
Cancer Causes Control. 2003 Feb;14(1):65-74
pubmed: 12708727
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):976-85
pubmed: 24646451
Endocrinol Metab Clin North Am. 2012 Jun;41(2):249-63, v
pubmed: 22682629
Br J Cancer. 2004 Jan 26;90(2):299-303
pubmed: 14735167
PLoS One. 2017 Dec 27;12(12):e0187741
pubmed: 29281666
Growth Horm IGF Res. 2009 Apr;19(2):146-55
pubmed: 18812263
Clin Chem. 2011 Apr;57(4):555-9
pubmed: 21285256
Clin Endocrinol (Oxf). 1993 Sep;39(3):357-62
pubmed: 7693379
J Clin Invest. 1983 Jun;71(6):1523-35
pubmed: 6345584
Alcohol Clin Exp Res. 2007 Aug;31(8):1269-85
pubmed: 17559547
J Clin Oncol. 1999 Mar;17(3):813-7
pubmed: 10071271
Endocr Rev. 1994 Feb;15(1):80-101
pubmed: 8156941
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1333-40
pubmed: 19423514
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):277-82
pubmed: 9484994
Psychoneuroendocrinology. 1992 Aug;17(4):335-42
pubmed: 1279737
Lancet. 2002 May 18;359(9319):1740-5
pubmed: 12049864
J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106
pubmed: 12122101
Diabetes Care. 2010 Jul;33(7):1674-85
pubmed: 20587728
Cytokine Growth Factor Rev. 1997 Mar;8(1):45-62
pubmed: 9174662
Am J Epidemiol. 2002 Aug 15;156(4):344-8
pubmed: 12181104
Ann Epidemiol. 2009 Dec;19(12):841-9
pubmed: 19944347
Diabetes Care. 2010 Oct;33(10):2257-9
pubmed: 20639451
Biochem J. 2015 May 1;467(3):453-60
pubmed: 25695641
Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8
pubmed: 18838726
Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704
pubmed: 14710348
Lancet Oncol. 2010 Jun;11(6):530-42
pubmed: 20472501
Proc Soc Exp Biol Med. 1997 Dec;216(3):319-57
pubmed: 9402139
Growth Horm IGF Res. 2010 Feb;20(1):8-18
pubmed: 19818658
Indian J Endocrinol Metab. 2014 Nov;18(Suppl 1):S53-62
pubmed: 25538878
Diabetes Metab. 2009 Jun;35(3):198-205
pubmed: 19297224
Am J Physiol. 1998 Jul;275(1):R308-14
pubmed: 9688993
J Clin Med. 2014 Dec 22;3(4):1561-74
pubmed: 26237614
Clin Endocrinol (Oxf). 2000 Mar;52(3):313-8
pubmed: 10718829
J Natl Cancer Inst. 2008 Feb 6;100(3):170-83
pubmed: 18230794
Cancer Epidemiol Biomarkers Prev. 2013 Jun;22(6):1102-9
pubmed: 23580698
CA Cancer J Clin. 2015 Nov-Dec;65(6):457-80
pubmed: 26375877
Int J Cancer. 2010 Apr 1;126(7):1702-15
pubmed: 19810099
Int J Biochem Cell Biol. 1996 Jun;28(6):619-37
pubmed: 8673727
Clin Exp Nephrol. 2010 Oct;14(5):440-4
pubmed: 20567872